Brief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
07/03/2024 21:41
March 7 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR ANNOUNCES TIMELINE FOR VOLUNTARILY DELISTING FROM
NASDAQ
* CYTEIR THERAPEUTICS INC: OFFICIAL DELISTING OF CO'S COMMON
STOCK
WILL BE EFFECTIVE ON OR ABOUT MARCH 28, 2024, TEN DAYS AFTER
FILING OF FORM 25.
* CYTEIR THERAPEUTICS: INTENDS TO FILE A CERTIFICATE OF
DISSOLUTION WITH DELAWARE SECRETARY OF STATE ON OR ABOUT MARCH
20, 2024
* CYTEIR THERAPEUTICS INC: EXPECTS TO FILE A FORM 25 WITH
SEC
RELATING TO VOLUNTARY DELISTING OF ITS COMMON STOCK ON OR ABOUT
MARCH 18, 2024
Source text for Eikon: ID:nBw8hGKsa
Further company coverage: CYT.O
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile